- Home
- QLGN vs RSLS Comparison
QLGN vs RSLS Comparison
Compare QLGN & RSLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- RSLS
- Stock Information
- Founded
- QLGN 1996
- RSLS 2002
- Country
- QLGN United States
- RSLS United States
- Employees
- QLGN N/A
- RSLS N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- RSLS Medical/Dental Instruments
- Sector
- QLGN Health Care
- RSLS Health Care
- Exchange
- QLGN Nasdaq
- RSLS Nasdaq
- Market Cap
- QLGN 3.4M
- RSLS 3.4M
- IPO Year
- QLGN N/A
- RSLS 2007
- Fundamental
- Price
- QLGN $4.18
- RSLS $4.65
- Analyst Decision
- QLGN
- RSLS Hold
- Analyst Count
- QLGN 0
- RSLS 1
- Target Price
- QLGN N/A
- RSLS N/A
- AVG Volume (30 Days)
- QLGN 54.9K
- RSLS 34.2K
- Earning Date
- QLGN 11-14-2024
- RSLS 11-14-2024
- Dividend Yield
- QLGN N/A
- RSLS N/A
- EPS Growth
- QLGN N/A
- RSLS N/A
- EPS
- QLGN N/A
- RSLS N/A
- Revenue
- QLGN N/A
- RSLS $8,183,000.00
- Revenue This Year
- QLGN N/A
- RSLS $17.47
- Revenue Next Year
- QLGN N/A
- RSLS $20.00
- P/E Ratio
- QLGN N/A
- RSLS N/A
- Revenue Growth
- QLGN N/A
- RSLS N/A
- 52 Week Low
- QLGN $3.34
- RSLS $4.09
- 52 Week High
- QLGN $30.50
- RSLS $29.00
- Technical
- Relative Strength Index (RSI)
- QLGN 43.01
- RSLS 39.12
- Support Level
- QLGN $3.53
- RSLS $4.09
- Resistance Level
- QLGN $4.39
- RSLS $4.89
- Average True Range (ATR)
- QLGN 0.33
- RSLS 0.38
- MACD
- QLGN 0.06
- RSLS -0.05
- Stochastic Oscillator
- QLGN 50.98
- RSLS 32.97
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.